BNO 1030 is developed by Ivano-Frankivsk National Medical University.

What development phase is BNO 1030 in?

BNO 1030 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

BNO 1030

Ivano-Frankivsk National Medical University · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	BNO 1030
Also known as	Imupret
Sponsor	Ivano-Frankivsk National Medical University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19 (PHASE4)
Study of Imupret Application in the Technology of Delayed Prescription of Antibiotics in Patients With Acute Tonsillitis (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BNO 1030 CI brief — competitive landscape report
BNO 1030 updates RSS · CI watch RSS
Ivano-Frankivsk National Medical University portfolio CI